-
Zheng stuns Keys as US Open upsets dim American hopes
-
Sobering reality: Curbs on alcohol in northeast Syria cause discontent
-
Jovic 'loses sanity five times over' to oust Eala and book Gauff clash
-
Wobbly Osaka 'shocked' to battle past Mertens and reach last 16
-
'Like a jewel': Japan's luxury ice revered by bars worldwide
-
Indian Oscar-nominated filmmaker turns camera on his cancer
-
'The flood is coming': How a Nepal principal saved 900 students
-
Argentina 'let off hook' by Australia as Kiss's winning run ends
-
Kiss's winning run ends as Argentina hold Australia to draw
-
Argentina threatens to sanction oil projects around Falklands
-
Alcaraz excited to face 'dangerous' Paul for US Open quarter-final berth
-
Gauff into round four at US Open after straight-set win
-
Prince William to represent King Charles III at Norway late King Harald's funeral
-
Bordeaux hammer Racing in Top 14 start as Bielle-Biarrey extends deal
-
Inter and Roma roar back to win thrillers and share top spot
-
Zheng, Potapova pull off upsets to reach US Open last 16
-
Don't stop them now: fans party for Freddie Mercury's 80th birthday
-
Swiatek into US Open fourth round in tight two-setter
-
AFP photographer wins top prize for Madagascar protest coverage
-
Werro wins in Brussels, as Russell and Dos Santos shine
-
Keys: 'I felt like I couldn't play tennis'
-
Kolbe breaks jaw and shoulder injury sidelines Savea
-
Simmonds stars as Pau upset Montpellier
-
US military strikes oil tankers as Iran vows tougher reprisals
-
Inter roar back in five-goal thriller with Napoli
-
Zheng rallies to stun Keys, Anisimova out in US Open third round
-
Haaland keeps Man City perfect in Premier League, blunt Spurs held
-
Bayern held to draw by stubborn Schalke
-
Hamilton worried by Ferrari pace while Antonelli prepares for a fight
-
Lens lose again ahead of Champions League date
-
Vuelta stage 15 shortened due to extreme heat, Mas consolidates lead
-
Olympic champion Zheng storms home to reach US Open last 16
-
Putin meets US envoys for Ukraine war talks
-
Big-spending Spurs must make better attacking decisions, says De Zerbi
-
Modric available for Croatia in Nations League
-
South Africa dominate New Zealand in second half to lead series
-
Potapova upsets 2025 US Open runner-up Anisimova
-
Kiefer Sutherland still in action, but ibuprofen lending helping hand
-
Gasly a 'class act' says Alpine boss after Monza pole
-
'Are we ready?' Oasis film captures band's frosty reunion
-
Athletic Bilbao crush Simeone's flat Atletico
-
Commemoration held for late Bosnian Serb war criminal Ratko Mladic
-
Stay far from battlefield, warns Japanese director in Vietnam War film
-
Haaland keeps new-look Man City perfect in Premier League, blunt Spurs held
-
Tens of thousands of Croatians protest over hazardous waste
-
Alpine's Gasly takes shock pole for Italian Grand Prix
-
Haaland heads unconvincing Man City top of Premier League
-
Nwaneri helps Dortmund to comeback win on Bundesliga debut
-
US envoys in Moscow as Russia and Ukraine vow not to hit capitals during talks
-
US military says destroys Iranian oil tankers after missile attacks
Moderna sues Pfizer, BioNTech for Covid-19 vaccine patent infringement
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"This groundbreaking technology was critical to the development of Moderna's own mRNA Covid-19 vaccine, Spikevax. Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna added.
US-based Pfizer said it has not received the lawsuit and declined to speak further, while Germany's BioNTech did not immediately reply to a request for comment.
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are both safe and effective.
The lawsuits -- to be filed in filed Friday both in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on coronaviruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
T.Perez--AT